Axitinib (off Label)
Inlyta
Sources
fda, as of 2026-11-07
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8a903e31-936e-4ed7-8a59-59f32374f338
Inlyta (axitinib) USPI, DailyMed setid 8a903e31-936e-4ed7-8a59-59f32374f338, published 03.16.2026, re-opened 2026-10-27 (raw/dailymed/inlyta.txt). The label has no adenoid cystic carcinoma indication (text search, 0 hits). Starting dose 5 mg twice daily; first dose reduction to 3 mg twice daily.
Brief source A2
guideline, as of 2026-11-07
https://www.esmoopen.com/article/S2059-7029(22)00232-0/fulltext
van Herpen C et al. Salivary gland cancer: ESMO-EURACAN Clinical Practice Guideline, ESMO Open, published 11.02.2022, doi 10.1016/j.esmoop.2022.100602 (guideline; opened in full 2026-10-27, four years old). AdCC section: no systemic treatment shown to improve OS in R/M AdCC; 10-year OS 40%; active surveillance for selected patients; systemic treatment for progressive or symptomatic disease; cisplatin 13% and CAP 25% response; antiangiogenics did not exceed 15% response; immune checkpoint inhibitors alone null; NOTCH inhibitor trial recommended for activated NOTCH; watch-and-wait for lung-only metastases; consider angiogenesis inhibitors or platinum chemotherapy when starting systemic treatment. The text says axitinib beat placebo; the trial's control was observation (see A21). NCCN could not be opened.
Brief source A7
publication, as of 2026-11-07
https://pubmed.ncbi.nlm.nih.gov/34315722/
Kang EJ et al. Randomized Phase II Study of Axitinib versus Observation in Patients with Recurred or Metastatic Adenoid Cystic Carcinoma, Clin Cancer Res 2021, doi 10.1158/1078-0432.CCR-21-1061, PMID 34315722 (publication abstract; opened 2026-10-27): n 60, progression within 9 months required, crossover allowed; axitinib 5 mg twice daily; 6-month PFS 73.0% vs 23.0%; median PFS 10.8 vs 2.8 months; ORR 0.0%; DCR 100% vs 51.9%; median OS not reached vs 27.2 months (P 0.226). PFS hazard ratio 0.25 (95% CI 0.14 to 0.48) is from the ESMO guideline (A7).
Brief source A21
publication, as of 2026-11-07
https://pubmed.ncbi.nlm.nih.gov/36898078/
Ferrarotto R et al. Phase II Clinical Trial of Axitinib and Avelumab in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma, J Clin Oncol 2023, PMID 36898078 (publication abstract; opened 2026-10-27): 40 enrolled, 28 evaluable; confirmed ORR 18% (95% CI 6.1 to 36.9); median PFS 7.3 months (3.7 to 11.2); 6-month PFS 57%; median OS 16.6 months; serious TRAEs 29% (all grade 3); avelumab discontinued by 12%; axitinib dose reduced in 26%. An earlier search-record figure of 7.4 months PFS is superseded by this abstract.
Brief source A22
publication, as of 2026-11-07
https://pubmed.ncbi.nlm.nih.gov/41973043/
Axitinib plus Avelumab in R/M ACC: Biomarker Analysis and Updated Results of the Phase II Trial, Clin Cancer Res 2026, doi 10.1158/1078-0432.ccr-25-4599, PMID 41973043 (publication abstract; opened 2026-10-27): 28 patients; median PFS 1.8 months for ACC-I vs 11.4 months for ACC-II (HR 0.14, P below 0.0001); the abstract says the regimen entered NCCN guidelines as the first immunotherapy-based option for ACC (NCCN itself not opened); 167-gene immune signature predicted benefit with immunotherapy combinations.
Brief source A23
registry, as of 2026-11-07
https://clinicaltrials.gov/study/NCT02859012
Randomized Phase II Study of Axitinib in Patients With Recurred or Metastatic Adenoid Cystic Carcinoma
ClinicalTrials.gov API v2 record, retrieved 2026-11-07